A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib

J Thorac Oncol. 2016 May;11(5):e63-e64. doi: 10.1016/j.jtho.2016.01.023.

Authors

Stefano Frega¹, PierFranco Conte¹, Matteo Fassan², Valentina Polo³, Giulia Pasello⁴

Affiliations

¹ Medical Oncology 2, Istituto Oncologico Veneto, Padua, Italy; Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy.
² Surgical Pathology Unit, Department of Medicine, University of Padua, Padua, Italy.
³ Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy.
⁴ Medical Oncology 2, Veneto Oncological Institute, Padua, Italy. Electronic address: giulia.pasello@ioveneto.it.

PMID: 27131295
DOI: 10.1016/j.jtho.2016.01.023

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / genetics
Afatinib
Aged
ErbB Receptors / genetics*
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Male
Mutation*
Prognosis
Quinazolines / therapeutic use*
Radiation-Sensitizing Agents / therapeutic use
Receptor, ErbB-2 / antagonists & inhibitors*

Substances

Quinazolines
Radiation-Sensitizing Agents
Afatinib
EGFR protein, human
ERBB2 protein, human
ErbB Receptors
Receptor, ErbB-2